Purpose To evaluate the amplitude of lung tumor motion and impact of tumor motion on dose delivered to the organs at risk (OARs) during lung stereotactic body radiation therapy (SBRT).Materials and methods This study included 55 patients (30 males and 25 females) with lung cancer who had a small gross tumor volume (GTV). SBRT lung cancer patients were treated with a prescribed dose of 60 Gy in 4 to 8 fractions. Radiotherapy plans were planned in Pinnacle 9.10 with two partial dynamic conformal arcs (DCAs) for the peripheral region (PR) and three to four partial DCAs for the central region (CR). The amplitude of tumor motion and their impact on the maximum dose delivered (D max ) to the OARs were evaluated in the upper lobe (UL) and lower lobe (LL) in cases of CR and PR tumor's localizations.
ResultsThe median tumor motions between CR and PR were 4.5 vs 2.2 mm in the UL and 12.5 vs 7.0 mm in the LL. Max dose delivered to the OARs between CR and PR in the UL and LL were as follows: 6.7 vs 8.9 Gy and 9.1 vs 11.7 Gy for the spinal cord; 15.2 vs 0.6 Gy and 22.4 vs 7.6 Gy for the heart; and 11.7 vs 10.8 Gy and 14.8 vs 9.8 Gy for the esophagus, respectively. Conclusion The dose received by the OARs depends on the amplitude of tumor motion and is relative to the OAR's location and motion, due to patient respiration and heart contribution.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.